Evidence map›Paper›PMID 34157102›Full record

ArticleNucleic acids research2021

Blasticidin S inhibits mammalian translation and enhances production of protein encoded by nonsense mRNA.

Kyle T Powers, Flint Stevenson-Jones, Sathish K N Yadav, Beate Amthor, Joshua C Bufton, Ufuk Borucu, Dakang Shen, Jonas P Becker, Daria Lavysh, Matthias W Hentze and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Kyle T PowersUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Flint Stevenson-JonesUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Sathish K N YadavUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Beate AmthorDepartment of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Research Center Heidelberg (KiTZ), University of Heidelberg, Heidelberg, Germany.
Joshua C BuftonUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Ufuk BorucuUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Dakang ShenUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.
Jonas P BeckerDepartment of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Research Center Heidelberg (KiTZ), University of Heidelberg, Heidelberg, Germany.
Daria LavyshDepartment of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Research Center Heidelberg (KiTZ), University of Heidelberg, Heidelberg, Germany.
Matthias W HentzeMolecular Medicine Partnership Unit (MMPU) European Molecular Biology Laboratory (EMBL) and University of Heidelberg, Heidelberg, Germany.
Andreas E KulozikDepartment of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Research Center Heidelberg (KiTZ), University of Heidelberg, Heidelberg, Germany.
Gabriele Neu-YilikDepartment of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Research Center Heidelberg (KiTZ), University of Heidelberg, Heidelberg, Germany.
Christiane SchaffitzelUniversity of Bristol, School of Biochemistry, University Walk, Bristol BS8 1TD, UK.ORCID 0000-0002-1516-9760
University of Bristol · GBHeidelberg University · DE

Funding

Biotechnology and Biological Sciences Research Council BB/R000484/1Wellcome TrustWellcome Trust 202904/Z/16/ZWellcome Trust 206181/Z/17/ZWellcome Trust 210701/Z/18/Z
6 · The paper itself

Abstract

Deciphering translation is of paramount importance for the understanding of many diseases, and antibiotics played a pivotal role in this endeavour. Blasticidin S (BlaS) targets translation by binding to the peptidyl transferase center of the large ribosomal subunit. Using biochemical, structural and cellular approaches, we show here that BlaS inhibits both translation elongation and termination in Mammalia. Bound to mammalian terminating ribosomes, BlaS distorts the 3'CCA tail of the P-site tRNA to a larger extent than previously reported for bacterial ribosomes, thus delaying both, peptide bond formation and peptidyl-tRNA hydrolysis. While BlaS does not inhibit stop codon recognition by the eukaryotic release factor 1 (eRF1), it interferes with eRF1's accommodation into the peptidyl transferase center and subsequent peptide release. In human cells, BlaS inhibits nonsense-mediated mRNA decay and, at subinhibitory concentrations, modulates translation dynamics at premature termination codons leading to enhanced protein production.

Indexed as

Cryoelectron MicroscopyHeLa CellsHumansNonsense Mediated mRNA DecayNucleosidesPeptide Chain Elongation, TranslationalPeptide Chain Termination, TranslationalPeptidesPeptide Termination FactorsProtein Synthesis InhibitorsRibosomesRibosome Subunits, Large, EukaryoticRNA, MessengerRNA, Transferblasticidin SNucleosidesPeptidesPeptide Termination FactorsProtein Synthesis InhibitorsRNA, MessengerRNA, Transfer

Identifiers

PMID34157102
PMCPMC8287960
OpenAlexW3166524949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.